Navigation Links
CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
Date:9/10/2012

SEATTLE and COPENHAGEN, Denmark, Sept. 10, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, announced today it has hired Mark W. Sawicki, Ph.D., to serve as the Company's new Vice President of Global Business Development. Dr. Sawicki will be focused on business development, sales management, and the integration and alignment of the Company's global sales and marketing team.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO )

"Mark brings broad experience and documented success in the pharmaceutical/biotechnology industry," said Gustavo Mahler, Chief Operations Officer of CMC Biologics.  "His results-oriented approach and business acumen will play a pivotal role in extending our track record of innovation, while helping us grow profitability and take full advantage of the global contract manufacturing market opportunities ahead. In his role as Vice President, Global Business Development, he will be responsible for realizing the full potential of the sales and marketing team and provide leadership to this exciting phase of CMC Biologics' growth".

"CMC Biologics is very well respected, has a growing global customer base, offers world-class analytical, process development and manufacturing services, and has recently introduced new innovative services and technologies to its offering, giving the company a very attractive growth potential." said Dr. Sawicki. "I see a bright future for CMC Biologics and am eager to be part of the experienced and dedicated team and the challenges ahead."

Dr. Sawicki brings 10 years of business development and sales management experience, consistently delivering on corporate revenue and market share goals in the pharmaceutical/biotechnology industry.  Prior, Sawicki was Vice President, Business Development-Europe for Albany Molecular Research, Inc. responsible for business development and sales activity in the European theater, as well as global key account management strategy.  He consistently increased sales revenue at rates far outpacing industry standards from the EU Theater and prior, the US, and developed market analysis models for AMRI to determine market factors to proactively envisage future geographic/business shifts and trends. He holds Ph.D. and B.S. degrees in biochemistry from State University of New York at Buffalo; is a member of the Editorial Advisory of Pharmaceutical Outsourcing; and has more than a dozen publications in drug discovery and biochemistry.

About CMC Biologics

CMC Biologics is a global contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world from its facilities in Europe and the USA.  The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production.  The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing.  Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark; Seattle, Washington; and Berkeley, California. More detailed information can be found at www.cmcbiologics.com.


'/>"/>
SOURCE CMC Biologics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):